GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy

GCPII 抑制剂用于治疗化疗引起的神经病变

基本信息

  • 批准号:
    8468134
  • 负责人:
  • 金额:
    $ 34.21万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-09 至 2017-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a common toxicity associated with anticancer treatment which can lead to early discontinuation of therapy and/or severely affect quality of life. Little is known about the mechanisms responsible for CIPN, and despite many CIPN therapeutic clinical trials, no standard evidence-based treatment exists. Excessive glutamate transmission has been implicated in the pathogenesis of peripheral neuropathy and neuropathic pain. Inhibition of the glial enzyme glutamate carboxypeptidase II (GCPII) has been shown to selectively dampen excessive glutamate transmission and alleviate neuropathic pain and protect peripheral nerves from the functional and histological deficits induced by chemotherapeutic agents. Based on these data, an orally bioavailable, thiol-based GCPII inhibitor was taken into clinical studies. Although the inhibitor was well-tolerated in Phase 1, subsequent immunological toxicities observed in GLP primate studies halted its development. Importantly the toxicity was not due to the GCPII mechanism, but rather due to the thiol moiety in the compound. As a class, thiol drugs have a risk of inducing hypersensitivity reactions. We now outline an iterative drug discovery plan to identify clinically viable non thiol GCPII inhibitors to test the hypothesis that this mechanism will provide therapeutic benefit to CIPN patients. Our iterative drug discovery plan includes a systematic zinc binding group replacement strategy, extensive in vitro drug-ability assessments, drug metabolism, in vivo pharmacokinetics, biomarker strategies, and evaluation of compounds in paclitaxel- and oxaliplatin-induced neuropathy and nerve crush efficacy experiments. Active compounds emerging from these efforts will be ready for IND enabling studies and ultimately clinical investigation in CIPN patients.
描述(由申请方提供):化疗诱导的周围神经病变(CIPN)是一种与抗癌治疗相关的常见毒性,可导致提前停止治疗和/或严重影响生活质量。对CIPN的机制知之甚少,尽管有许多CIPN治疗性临床试验,但没有标准的循证治疗。过量的谷氨酸传递与周围神经病变和神经性疼痛的发病机制有关。抑制神经胶质酶谷氨酸羧肽酶II(GCPII)已显示出选择性地抑制过量的谷氨酸传递和减轻神经性疼痛,并保护周围神经免受化疗药物诱导的功能和组织学缺陷。基于这些数据,一种口服生物可利用的基于巯基的GCPII抑制剂被纳入临床研究。尽管该抑制剂在I期研究中耐受良好,但随后在GLP灵长类动物研究中观察到的免疫毒性阻止了其发展。重要的是,毒性不是由于GCPII机制,而是由于化合物中的硫醇部分。作为一类,硫醇类药物具有诱导超敏反应的风险。我们现在概述了一个迭代的药物发现计划,以确定临床上可行的非巯基GCPII抑制剂,以测试假设, 该机制将为CIPN患者提供治疗益处。我们的迭代药物发现计划包括系统的锌结合基团替代策略,广泛的体外药物能力评估,药物代谢,体内药代动力学,生物标志物策略,以及在紫杉醇和奥沙利铂诱导的神经病变和神经挤压疗效实验中评价化合物。从这些努力中产生的活性化合物将准备用于IND使能研究,并最终用于CIPN患者的临床研究。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Barbara Stauch Slusher其他文献

Immunocytochemical localization of the N‐acetyl‐aspartyl‐glutamate (NAAG) hydrolyzing enzyme N‐acetylated α‐linked acidic dipeptidase (NAALADase)
N-乙酰-天冬氨酰-谷氨酸 (NAAG) 水解酶 N-乙酰化 α-连接酸性二肽酶 (NAALADase) 的免疫细胞化学定位

Barbara Stauch Slusher的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Barbara Stauch Slusher', 18)}}的其他基金

High throughput screen for discovery of N-acetyltransferase 8 Like (NAT8L) inhibitors
用于发现 N-乙酰转移酶 8 样 (NAT8L) 抑制剂的高通量筛选
  • 批准号:
    10319002
  • 财政年份:
    2020
  • 资助金额:
    $ 34.21万
  • 项目类别:
High Throughput Screen for Discovery of N-Acetyltransferase 8 Like (NAT8L) Inhibitors
用于发现 N-乙酰转移酶 8 样 (NAT8L) 抑制剂的高通量筛选
  • 批准号:
    10704342
  • 财政年份:
    2020
  • 资助金额:
    $ 34.21万
  • 项目类别:
Cell-targeted glutamine antagonists as a novel therapy for lymphoma
细胞靶向谷氨酰胺拮抗剂作为淋巴瘤的新疗法
  • 批准号:
    10408137
  • 财政年份:
    2018
  • 资助金额:
    $ 34.21万
  • 项目类别:
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease
外泌体分泌调节作为阿尔茨海默病的新型治疗方法
  • 批准号:
    10424423
  • 财政年份:
    2018
  • 资助金额:
    $ 34.21万
  • 项目类别:
Regulation of Exosome Secretion as a novel therapeutic approach for Alzheimer's Disease
外泌体分泌调节作为阿尔茨海默病的新型治疗方法
  • 批准号:
    10183123
  • 财政年份:
    2018
  • 资助金额:
    $ 34.21万
  • 项目类别:
Cell-targeted glutamine antagonists as a novel therapy for lymphoma
细胞靶向谷氨酰胺拮抗剂作为淋巴瘤的新疗法
  • 批准号:
    10197023
  • 财政年份:
    2018
  • 资助金额:
    $ 34.21万
  • 项目类别:
Identification of novel system xc- inhibitors
新型系统 xc-抑制剂的鉴定
  • 批准号:
    8359138
  • 财政年份:
    2012
  • 资助金额:
    $ 34.21万
  • 项目类别:
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy
GCPII 抑制剂用于治疗化疗引起的神经病变
  • 批准号:
    8296943
  • 财政年份:
    2012
  • 资助金额:
    $ 34.21万
  • 项目类别:
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy
GCPII 抑制剂用于治疗化疗引起的神经病变
  • 批准号:
    8839732
  • 财政年份:
    2012
  • 资助金额:
    $ 34.21万
  • 项目类别:
GCPII Inihibitors for the treatment of chemotherapy-induced neuropathy
GCPII 抑制剂用于治疗化疗引起的神经病变
  • 批准号:
    8658046
  • 财政年份:
    2012
  • 资助金额:
    $ 34.21万
  • 项目类别:

相似海外基金

Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10707830
  • 财政年份:
    2023
  • 资助金额:
    $ 34.21万
  • 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
  • 批准号:
    479728
  • 财政年份:
    2023
  • 资助金额:
    $ 34.21万
  • 项目类别:
    Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
  • 批准号:
    10884567
  • 财政年份:
    2023
  • 资助金额:
    $ 34.21万
  • 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
  • 批准号:
    10751964
  • 财政年份:
    2023
  • 资助金额:
    $ 34.21万
  • 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
  • 批准号:
    486321
  • 财政年份:
    2022
  • 资助金额:
    $ 34.21万
  • 项目类别:
    Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10676786
  • 财政年份:
    2022
  • 资助金额:
    $ 34.21万
  • 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
  • 批准号:
    10440970
  • 财政年份:
    2022
  • 资助金额:
    $ 34.21万
  • 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
  • 批准号:
    10642998
  • 财政年份:
    2022
  • 资助金额:
    $ 34.21万
  • 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
  • 批准号:
    10482465
  • 财政年份:
    2022
  • 资助金额:
    $ 34.21万
  • 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
  • 批准号:
    10191053
  • 财政年份:
    2020
  • 资助金额:
    $ 34.21万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了